Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by retiredcf on Jun 30, 2020 2:07pm

McWhirter Link

Second stock in the clip. GLTA

https://www.bnnbloomberg.ca/video/robert-mcwhirter-s-past-picks~1986929
Comment by retiredcf on Jun 30, 2020 2:11pm
PAST TOP PICK   Antibe Therapeutics Inc. (ATE-X) June 30, 2020   (A Top Pick Aug 01/19, Up 24%) There's been a lot going here: the reported good phase 2 drug test results. They did financing recently and are planning for phase 3 which will cost $50 million, so they have enough cash for 18 months. The next phase will start in Q2 2021 and last two years. Generally, drugs ...more  
Comment by MUGMODs on Jun 30, 2020 2:16pm
This post has been removed in accordance with Community Policy
Comment by bringon10bagger on Jun 30, 2020 5:38pm
He didn't even convey the point of partnering with big pharma for phsse 3, huge miss on his part........imo still a holder and loading up at these levels....and what a stupid comment to say with phase 2 complete would fetch 600M.....all relevant to how big the prize is and ATE's case........HUGE prize, BEST in CLASS NSAID's multibillion payback .
Comment by MUGMODs on Jun 30, 2020 5:42pm
This post has been removed in accordance with Community Policy
Comment by RalphRalph on Jun 30, 2020 6:01pm
McWhirter's opinion about a current $600 million valuation seems reasonable to me.   I don't believe he said that's what it would or should fetch in a buyout; just that that number was a reasonable valuation given where Antibe is in the development process.  I doubt that any big Pharma would currently offer Antibe (with a $125 million market cap) a $1 billion ...more  
Comment by PhillUpBanks on Jun 30, 2020 6:14pm
Ralph I do not believe the latest Deal for 28 million(or whatever the exact amount) was intended for phase 3. The company has stated this a few times. I believe they have another direction in mind or they could have raised enough to go through phase 3 alone.. but i am just making assumptions like everyone else. None of us "stock house experts" really know I guess we just have to   ...more  
Comment by RalphRalph on Jun 30, 2020 6:50pm
My guess would be that Antibe's  strategy regarding the recent raise was to have enough cash to be able to fund expenses related to initiating Phase 3 - although it obviously is not enough to finish it.    It would not be prudent to delay the start of Phase 3 until a major market partnership has been reached, if the company expects that negotiation to take a prolonged period ...more  
Comment by MUGMODs on Jun 30, 2020 11:00pm
This post has been removed in accordance with Community Policy
Comment by bringon10bagger on Jul 01, 2020 10:42am
Often wondered if Dan and Team has an minimum exit point in terms of $$$, a Bayer should be 1st up at table .....with their blank cheque...and then again any big pharma-all cashed up, could easily go to highest bidder. 
Comment by MUGMODs on Jul 01, 2020 8:58pm
This post has been removed in accordance with Community Policy
Comment by dns236 on Jun 30, 2020 4:07pm
McWhirter believes strongly in "Stop Loss Orders" and him and his family are shown to hold no shares. So he got out with a good profit!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities